Article info

Download PDFPDF
Letter
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Authors

  1. Correspondence to Dr Craig P Thompson, University of Warwick Warwick Medical School, Coventry CV4 7HL, UK; craigpeterthompson{at}gmail.com
View Full Text

Citation

Wellens J, Edmans M, Obolski U, et al
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Publication history

  • Received October 13, 2021
  • Accepted November 6, 2021
  • First published December 15, 2021.
Online issue publication 
November 15, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.